Vonoprazan/amoxicillin/clarithromycin

Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[1][4] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.[1][4]

Vonoprazan/amoxicillin/clarithromycin
Combination of
VonoprazanPotassium-competitive acid blocker
AmoxicillinBeta-lactam antibiotic
ClarithromycinMacrolide antibiotic
Clinical data
Trade namesVonosap, Voquezna Triple Pak
License data
ATC code
Legal status
Legal status
Identifiers
KEGG

It was approved for medical use in Japan in 2016,[3] and in the United States in May 2022.[1][2][5][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

References
  1. "Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit". DailyMed. U.S. National Library of Medicine. 21 June 2022. Archived from the original on 3 July 2022. Retrieved 3 July 2022.
  2. "Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults" (Press release). Phathom Pharmaceuticals. 3 May 2022. Archived from the original on 10 May 2022. Retrieved 9 May 2022 – via GlobeNewswire.
  3. "Vonosap pack 400, Vonosap pack 800 and Vonopion pack (triple-drug blister packs containing Takecab tablet) Now Available for Helicobacter pylori[*] Eradication in Japan". Takeda. 7 June 2016. Archived from the original on 10 May 2022. Retrieved 9 May 2022.
  4. Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S (July 2021). "Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis". Advances in Therapy. 38 (7): 3937–3947. doi:10.1007/s12325-021-01784-w. PMC 8280045. PMID 34091865.
  5. "FDA NDA approval" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 12 May 2022. Retrieved 12 May 2022.
  6. "Voquezna Triple Pak (amoxicillin, clarithromycin, and vonoprazan) FDA Approval History". Drugs.com.
  7. "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Retrieved 22 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.

Further reading
  • Kajihara Y, Shimoyama T, Mizuki I (February 2017). "Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication". Scandinavian Journal of Gastroenterology. 52 (2): 238–241. doi:10.1080/00365521.2016.1250157. PMID 27806639. S2CID 25801431.
  • Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. (9 July 2019). "A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study". Digestion. 101 (5): 608–614. doi:10.1159/000501608. PMID 31288235. S2CID 195871882.
  • Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, et al. (November 2020). "Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility". Journal of Gastroenterology. 55 (11): 1054–1061. doi:10.1007/s00535-020-01723-6. PMID 32930864. S2CID 221674785.
  • "Vonoprazan". Drug Information Portal. U.S. National Library of Medicine.
  • "Amoxicillin". Drug Information Portal. U.S. National Library of Medicine.
  • "Clarithromycin". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.